Brincidofovir Patent Expiration
Brincidofovir is Used for treating human smallpox disease. It was first introduced by Emergent Biodefense Operations Lansing Llc
Brincidofovir Patents
Given below is the list of patents protecting Brincidofovir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tembexa | US10112909 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | Oct 10, 2034 | Emergent Biodefense |
| Tembexa | US10487061 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | Oct 10, 2034 | Emergent Biodefense |
| Tembexa | US8962829 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | Oct 10, 2034 | Emergent Biodefense |
| Tembexa | US9371344 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | Oct 10, 2034 | Emergent Biodefense |
| Tembexa | US9303051 | Phosphonate ester derivatives and methods of synthesis thereof | Jul 30, 2034 | Emergent Biodefense |
| Tembexa | US9303051 | Phosphonate ester derivatives and methods of synthesis thereof | Jul 30, 2034 | Emergent Biodefense |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Brincidofovir's patents.
Latest Legal Activities on Brincidofovir's Patents
Given below is the list recent legal activities going on the following patents of Brincidofovir.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Eligible | 08 Jul, 2025 | US9303051 |
| FDA Final Eligibility Letter | 20 May, 2025 | US9303051 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US9303051 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9303051 |
| transaction for FDA Determination of Regulatory Review Period | 07 Feb, 2024 | US9303051 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Dec, 2023 | US9371344 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Sep, 2023 | US9303051 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 May, 2023 | US10487061 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 14 Feb, 2023 | US10112909 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 14 Feb, 2023 | US8962829 |
Brincidofovir's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Brincidofovir:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection | SymBio Pharmaceuticals | NA |
COMPLETED
(Aug 1, 2026)
| PHASE2 |
| Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study | National Institute of Neurological Disorders and Stroke (NINDS) | NA |
RECRUITING
(Jul 20, 2026)
| PHASE2 |